A single-centre comparison of the clinical outcomes at 6 months of renal transplant recipients administered Adoport<sup>®</sup> or Prograf<sup>®</sup> preparations of tacrolimus.

Clin Kidney J · 2013 · PMC5094386 · PMID 27818747

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In deceased donor recipients, BPAR occurred more frequently in patients receiving Adoport ® than Prograf ® (21.1 and 8.8%, respectively) although this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.